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Contribution of renal angiotensin II type I receptor to gene expressions
in hypertension-induced renal injury. Recent evidence indicates that
transforming growth factor-fit (TGF-f31) plays an important role in renal
fibrosis via stimulation of extracellular matrix synthesis. The present study
was undertaken to investigate the role of angiotensin II type I receptor
(AT1 receptor) in hypertension-induced renal injury. Twenty-two-week-
old stroke-prone spontaneously hypertensive rats (SHRSP), which had
established hypertension and moderate renal damage, were orally given
TCV-116, a selective non-peptide AT1 receptor antagonist (0.1, 1 or 10
mg/kg/day), enalapril (10 mg/kg/day) or vehicle once a day for 10 weeks.
At the end point of the treatment, we examined renal function, the gene
expressions of TOE-fl and extracellular matrix components in the
interstitium [collagen types I (COI) and III (COIlI), fibronectin (EN)] and
the basement membrane (COIV and laminin), and renal microscopic
morphology in rats aged 32 weeks. In vehicle-treated 32 week-old SHRSP
with renal dysfunction and nephrosclerosis, renal mRNA levels for
TOF-f 1, COl, COT!!, EN, COW were all several-fold higher than in
WKY. Thus, renal TOF-jll gene expression was enhanced in SHRSP,
which may contribute to the increased renal expressions of COT, COIlI,
EN, COW in SHRSP. Treatment with TCV-116 (0.1 mg/kg/day) in
SHRSP, in spite of no reduction of blood pressure, decreased renal
mRNA levels for TOE-fl, CO!, COIlI, EN, COIV, being accompanied by
the significant decrease in urinary protein and albumin excretion, blood
urea nitrogen and plasma creatinine. Treatment with TCV-1 16 (10
mg/kg/day) in SHRSP decreased mRNAs for TOE-fl, COl, COIl!, EN
and COIV to almost the same levels as WKY, being associated with
normalization of urinary protein and albumin excretion and the preven-
tion of nephrosclerosis, as judged by microscopic histological observations.
On the other hand, the effects of enalapril (10 mg/kg/day) on the above
mentioned mRNA levels, renal function and renal morphology were
weaker than those of TCV-116 (10 mg/kg/day) and were as much as
TCV-116 (1 mg/kg/day), These results suggest that independently of
hypotensive action, AT1 receptor antagonist has a potent renal protective
effect by inhibiting the gene expression of renal TOE-fl and extracellular
matrix components.
Although hypertension is n major risk factor for renal injury [1],
the mechanism of development of renal sclerosis in hypertensive
patients and animals remains to be elucidated. Stroke-prone
spontaneously hypertensive rats (SHRSP), a substrain of sponta-
neously hypertensive rats (SHR), are considered a useful model of
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human malignant hypertension. SHRSP characteristically develop
severe nepbrosclerosis and have been extensively studied as an
example of hypertension-induced renal injury [2—4].
Investigations on effects of angiotensin converting enzyme
(ACE) inhibitors [5, 6] or an angiotensin II type I (AT1) receptor
antagonist [7] on renal function of SHRSP suggest the important
role of renin-angiotensin system in renal injury of SHRSP,
although the mechanism is not fully understood. While the
changes in renal hemodynamics such as the reduction of glomer-
ular capillary pressure are reported to be responsible for the renal
protective effects by these drugs [8—11], several recent works have
demonstrated the dissociation between the time course of anti-
proteinuric and hemodynamic effects by ACE inhibitors [12—14].
Recent histological study shows that ACE inhibitors and AT1
receptor antagonist can prevent renal and extrarenal vascular
structural damage to some extent in rats with chronic renal
failure, independent of their depressor effect on systemic blood
pressure or local glomerular pressure [15]. Thus, the renal pro-
tective effects by inhibition of renin-angiotensin system appear to
be at least in part mediated by unknown mechanisms other than
renal hemodynamic effects [12—15]. Furthermore, it is possible
that the renal protective effects of ACE inhibitors are in part due
to the activation of kinin-kallikrein system and the increased
prostaglandins [16, 17].
Transforming growth factor-fit (TOF-131) is a multifunctional
growth factor and plays an important role in cell proliferation or
hypertrophy, ehemoattraction of leukocytes and monocytes mi-
gration, and synthesis of extracellular matrix [18—20]. Recent
evidence [21—24] supports the notion that TGF-/31 is involved in
fibrosis in several experimental renal diseases by increasing the
synthesis of extracellular matrix. However, the role of TGF-f 1 in
hypertension-mediated renal injury remains to be determined.
Furthermore, it is unknown whether or not angiotensin II (Ang
II) contributes to the in vivo gene expression of renal TGF-f31.
Our present study was undertaken to examine whether or not
TGF-f 1 might be responsible for hypertensive renal injury and
whether renal injury by Ang II is mediated by TGF-/31. For this
purpose, we studied the gene expression of TOE-fl and extracel-
lular matrix proteins in the kidney of SHRSP and the effects of
TCV-116 [25—28], a non-peptide selective AT1 receptor antago-
nist, on these gene expressions.
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Methods
Animals
SHRSP and Wistar-Kyoto rats (WKY) were donated to Takeda
Chemical Industries, LTD. (Osaka, Japan) by Dr. K. Okamoto
(Department of Pathology, Kyoto University, Kyoto, Japan) in
1972, and have been maintained by selective mating at Takeda
Chemical Industries, Ltd. since 1972 [3, 29]. Male SHRSP and
age-matched control WKY [3, 29] were fed a standard laboratory
chow (CE2, Clea Japan, Tokyo, Japan) and given tap water ad
libitum.
Drugs
TCV-116 and enalapril maleate, which were synthesized by
Takeda Chemical Industries, Ltd., were suspended with small
amount of gum arabic solution for oral administration.
Experimental protocol
Anti-hypertensive drugs are often used in hypertensive patients
with renal dysfunction, although the renal protective effect of
anti-hypertensive drugs in such patients is still unclear. Thus, it is
clinically very important to investigate the renal protective effects
of anti-hypertensive drugs in hypertensive rats with established
hypertension and renal damage. SHRSP at 22 weeks have estab-
lished hypertension (systolic BP greater than 200 mm Hg) and
moderate renal damage; by 32 weeks such rats have renal fibrosis
and renal insufficiency [4, 5, 6, 29]. Therefore, in the present study
drug treatment of SHRSP was carried out from the age of 22 to 32
weeks. Twenty-two-week-old male SHRSP were randomly sepa-
rated into five groups, and there was no difference in blood
pressure, heart rate, body weight and urinary protein and albumin
excretion among each group before the experiments. The animals
were orally given TCV-116, enalapril or vehicle (2 ml/kg) by
gastric gavage in the morning once a day. TCV-116 were given to
SHRSP at the dose of 0.1, 1 or 10 mg/kg/day. The hypotensive
effects of these 3 doses of TCV-116 have been examined in detail
in other hypertensive models, including SHR and two-kidney,
one-clip hypertensive rats [28]. Preliminary experiments showed
that 0.1 mg/kg/day of TCV-1 16 did not significantly lower blood
pressure in SHRSP throughout 10 weeks of treatment, (manu-
script in preparation). Therefore, in the present study, treatment
with this dose of TCV-116 was performed to study the effect of
AT1 receptor antagonist not mediated by systemic blood pressure.
Enalapril is the most popular ACE inhibitor and has been well
characterized, with respect to the hypotensive effects and the renal
protective effects in SHRSP [5, 6] and rats with renal failure [9, 11,
12], which led us to use enalapril as an ACE inhibitor in the
present study, to compare with AT1 receptor antagonist. Previous
reports show that 10 to 15 mg/kg of enalapril has significant
hypotensive and renal protective effects in SHRSP [5, 6]. There-
fore, this dose of enalapril was used in the present study. Control
SHRSP were given only vehicle (5% gum arabic solution).
Treatment with the above mentioned drugs or vehicle were
carried out for 10 weeks (from the age of 22 to 32 weeks). Blood
pressure, heart rate and body weight were measured periodically
throughout drug treatment. The measurements of blood pressure
were all carried out at five hours after oral dosing of each drug,
because previous studies indicated that the maximal hypotensive
effects of TCV-116 occur at 5 hours after oral administration [28].
For measurement of urinary protein and albumin excretion, rats
were individually housed in metabolic cages two days before
termination of 10 weeks of drug treatment, and urine was
collected for 24 hours. After 10 weeks of treatment, the above five
groups of SHRSP with the age of 32 weeks and age-matched
WKY were killed by decapitation and trunk blood was collected.
Kidneys were rapidly excised, weighed, frozen in liquid nitrogen
and stored at —80°C until the extraction of total tissue RNA.
For renal histological study, 22-week-old male SHRSP were
treated with vehicle, TCV-116 (0.1 mg/kg/day), TCV-116 (10
mg/kg/day) and enalapril (10 mg/kg/day) for 10 weeks, as de-
scribed above, decapitated, and kidneys were removed to examine
histology as described below.
Extraction of renal total RNA
Total RNA was extracted from kidneys, according to the
method of Chomczynski and Sacchi [30] with a minor modilica-
tion. In brief, frozen renal tissues were homogenized with a
Polytron homogenizer (PCU-11, Kinematica AG, Littau/Luzern,
Switzerland) for 60 seconds at speed dial 10 in denaturing solution
(4 M guanidinium thiocyanate, 25 m sodium citrate (pH 7.0), 0.1
M 2-mercaptoethanol, 0.5% N-lauroylsarcosine). The homogenate
was added to 1/10 vol of 2 M sodium acetate (pH 4), 1 vol of
water-saturated phenol and 1/2 vol of chloroform, and centrifuged
at 10,000 X g at 4°C for 20 minutes. The resulting upper aqueous
phase was transferred to a fresh tube and precipitated by addition
of 1 vol of isopropanol followed by centrifugation. The precipitate
was dissolved in the above denaturing solution, incubated with 3.5
M lithium chloride at 4°C for 18 hours and then centrifuged. After
the centrifugation, the RNA pellet was washed with 3 M lithium
chloride and then with 70% ethanol. Finally, the RNA pellet was
dissolved in 0.1% diethyl pyrocarbonate-treated water and stored
at —80°C until use, The RNA concentration was spectrophoto-
metrically determined at 260 nm.
Northern blot hybridization
Thirty micrograms of total RNA from kidneys was denatured by
incubating with 1 M deionized glyoxal and 50% dimethyl sulfoxide
at 50°C for one hour [31], electrophoresed on a 1% agarose gel at
50 V, and transferred to a nylon membrane (Gene Screen Plus,
E.l. du Pont de Nemours & Co., NEN Products, Boston, Massa-
chusetts, USA). Each cDNA probe was labeled with (32P)-dCTP
(specific activity 3000 Ci/mM; E.l. du Pont de Nemours) by
random primer extension method [32] with a Random Primer
DNA Labeling Kit (Takara, Kyoto, Japan). Prehybridization and
hybridization were performed according to the manufacturer's
instruction. In brief, the membranes were prehybridized in a
solution containing 50% formamide, 5 X Denhardt (Ficoll, poly-
vinylpyrrolidone and bovine serum albumin, 1 mg/mI each), 5 X
SSPE (0.75 M sodium chloride, 50 ifiM sodium phosphate, 5 mM
ethylenediaminetetraacetic acid), 1% sodium dodecyl sulfate
(SDS) and 200 jg/ml denatured salmon sperm DNA at 42°C for
four hours. Then the membranes were hybridized with 32P-labeled
cDNA (1 to 2 X 106 dpm/ml) at 42°C for 24 hours in fresh
hybridization solution which was identical to the prehybridization
solution except for the absence of salmon sperm DNA. The
membranes were washed in 2 X SSPE at room temperature for 30
minutes, in 2 x SSPE and 2% SDS twice at 65°C for 45 minutes,
and in 0.1 X SSPE at room temperature for 30 minutes. After
washing, the membranes were exposed to Kodak XAR-5 film
between two intensifying screens at —70°C. The nylon membrane
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Table 1. Body weight, kidney weight, blood pressure and heart rate in WKY and SHRSP at 10 weeks after drug treatment
WKY
SHRSP
Vehicle
TCV
(0.1 mg)
TCV
(1 mg)
TCV
(10 mg)
Enalapril
(10 mg)
Body weight g
Kidney weight mg/g body wt
Blood pressure mm Hg
455 12"
7.38 0,26"
132 2"
345 12
9.76 0.36
222 10
383 6
8.71 0.15"
208 7
375 7
8.11 0.15"
183 4"
355 8
8.25 0.25"
142 8"
376 16
8.66 0.35a
178 3"
Heart rate bpm 354 13 353 20 329 17 387 12 391 20 368 20
Abbreviations are: WKY, Wistar-Kyoto rats; SHRSP, stroke-prone spontaneously hypertensive rats; Vehicle, vehicle-treated SHRSP; TCV (0.1 mg),
TCV-116 (0.1 mg/kg/day)-treated SHRSP; TCV (1 mg), TCV-116 (1 mg/kg/day)-treated SHRSP; TCV (10 mg), TCV-116 (10 mg/kg/day)-treated
SHRSP; Enalapril (10 mg), enalapril (10 mg/kglday)-treated SHRSP.p < 005 bP < 0.01 vs. vehicle-treated SHRSP
was stripped off by boiling in 0.1 X SSC solution containing 1%
SDS, and then rehybridized with other cDNA probes. All renal
RNA samples from six groups of rats were electrophoresed on the
same agarose gel, transferred to the same membrane and hybrid-
ized with each eDNA probe at the same time, thereby allowing for
the comparison of mRNA levels among all six groups of rats.
To evaluate tissue mRNA levels, an optical scanner (EPSON
GT-8000, Seoko, Tokyo, Japan) was utilized for digitizing auto-
radiograms. The autoradiogram bands in the digitized image were
measured for their density with the use of the public domain NIH
Image program and a computer (Macintosh LC-III, Apple Com-
puter, Inc., USA). For all RNA samples, the density of an
individual mRNA band was normalized for that of GAPDH
mRNA band, to correct for the difference in RNA loading and/or
transfer.
cDNA probes
cDNA probes used were as follows. Rat renin DNA was a 0.70
kb KpnI/KpnI fragment, provided by Dr. A. Fukamizu (Institute
of Applied Biochemistry, Tsukuba University, Ibaraki, Japan)
[33]. Rat TGF-/31 cDNA was a 1.0 kb HindIII/XbaI fragment
from Dr. S.W. Qian (Laboratory of Chemoprevention, NIH,
Bethesda, Maryland, USA) [34]. Rat fibronectin eDNA was a 0.27
kb Hindill/EcoRl fragment from Dr. R.O Hynes (Center for
Cancer Research, Massachusetts Institute of Technology, Massa-
chusetts, USA) [35]. Rat al (I) collagen cDNA was a 1.3 kb
PstI/BamHI fragment from Dr. D. Rowe (Department of Pediat-
rics, University of Connecticut, Connecticut, USA) [361. Mouse
cDNAs for al (III) collagen [37], al (IV) collagen [38], and
laminin Bi chain [39] were the fragments of 1.8 kb EcoRI/EcoRI,
0.83 kb AvaI/PstI, 0.65 BamHItEcoRI, respectively, from Dr. Y.
Yamada (Laboratory of Developmental Biology, National Insti-
tute of Dental Research, Bethesda, USA). Rat glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was a 1.3 kb PstI/PstI
fragment from Dr. P. Fort (Laboratoire de Biologie Moleculaire,
Universite De Montpellier II, France) [40].
Measurement of blood pressure
Systolic blood pressure was measured by the tail-cuff method
(Riken Kaihatsu PS-8000, Japan).
Measurement of plasma renin concentration
Plasma renin concentrations (PRC) were measured as the rate
of Ang I generation from rat plasma angiotensinogen, as de-
scribed [41]. In brief, rat plasma samples were incubated with
48-hour nephrectomized rat plasma containing a excess of renin
substrate (2 tLM angiotensinogen) at 37°C in 0.1 M sodium
phosphate buffer (pH 7.0) containing protease inhibitors, and the
generated Mg I was measured by radioimmunoassay.
Histological examination
SHRSP, subjected to oral administration of vehicle, 0.1 or 10
mg/kg/day of TCV-116 or 10 mg/kg/day of enalapril for 10 weeks
(from the age of 22 to 32 weeks), as described above, and
age-matched WKY were decapitated, kidneys were removed,
fixed in 10% phosphate-buffered formalin, embedded in paraffin,
cut into 4 tim-thick sections, and Azan staining of the sections
were carried out to examine renal fibrosis. Semiquantitative
assessment was carried out in standard transverse sections
through the hilum of each kidney to include the apex of the
pyramid, the corticomedullary junction and cortex. Parameters
scored were as follows: fibrinoid necrosis in glomerulus; atrophy
of the epithelium, hypertrophy of basement membrane and
hyaline cast with dilatation in renal tubules; fibrinoid necrosis and
hypertrophy in arterioles; hyalinoid hypertrophy of intima in
artery; interstitial fibrosis. The criteria scoring was as follows:
score 0, intact; score 1, very mild; score 2, mild; score 3, moderate;
score 4, severe.
Miscellaneous measurements
Urinary protein was measured using a A/G-B test (Wako,
Osaka, Japan) based on Biuret reaction, and urinary albumin was
measured using an Albumin-B test with bromcresol green
(Wako). Blood urea nitrogen (BUN) and plasma creatinine were
also measured using their respective kit (Wako).
Statistical analysis
All values were expressed as mean SEM. Statistical signifi-
cance was determined using ANOVA and Duncan's multiple
range test, except for the use of Kruskal-Wallis ANOVA and
Wilcoxon's test for histological data. Differences were considered
statistically significant at a value of P < 0.05.
Results
Effects of TCV-116 and enalapril on body weight, kidney weight,
blood pressure and heart rate
As shown in Table 1, body weight of SHRSP was unchanged by
treatment with TCV-116 or enalapril. However, kidney weight in
SHRSP, which was larger than WKY (P °zz 0.01), was significantly
reduced by 10 weeks of treatment with three doses of TCV-116
(P < 0.01) or enalapril (P < 0.05).
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Fig. 1. Urinary protein excretion (A), albumin
excretion (B), BUN (C) and plasma creatinine
(D) in WKY and SHRSP after 10 weeks of
treatment with vehicle, TCV-116 or enalapriL
Abbreviations are: W, WKY; V, vehicle-treated
SHRSP; T (0.1), TCV-116 (0.1 mg/kg/day)-
treated SHRSP; T (1), TCV-116 (1 mg/kg/day)-
treated SHRSP; T (10), TCV-116 (10 mg/kg/
day)-treated SHRSP; E (10), enalapril (10 mg/
kg/day)-treated SHRSP; UprotV, urinary protein
excretion; UAIbV, urinary albumin excretion;
BUN, blood urea nitrogen. Each bar represents
the mean Each group included 5 animals.
* P < 0.01 vs. V (vehicle-treated SHRSP).
Table 1 also shows systolic blood pressure at 10 weeks after
treatment with vehicle, TCV-116 or enalapril, and the measure-
ments of blood pressure were all carried out at five hours after
oral administration. Systolic blood pressure in vehicle-treated
SHRSP (222 10 mm Hg) was higher than age-matched WKY
(132 2 mm Hg; P < 0.01). Ten weeks of treatment with
TCV-116 at 0.1 mg/kg/day failed to decrease blood pressure in
SHRSP. On the other hand, treatment with 1 and 10 mg/kg/day of
TCV-116 and 10 mg/kg/day of enalapril lowered blood pressure
(P < 0.01). There was no significant difference in blood pressure
between WKY and TCV-116 (10 mg/kg/day)-treated SHRSP.
Heart rate was affected by neither TCV-116 nor enalapril.
Effects of TCV-116 and enalapril on renal function
As shown in Figure 1A and B, urinary protein and albumin
excretion (96.9 9.6 and 53.9 6.9 mg/24h/100 g body weight,
respectively) in vehicle-treated SHRSP were 8.0-fold and 25.7-
fold, respectively, greater than those in WKY. Ten weeks of
treatment with TCV-116 (0.1, 1 and 10 mg/kg/day) and enalapril
(10 mg/kg/day) in SHRSP significantly decreased both urinary
protein and albumin excretion (P < 0.01 vs. vehicle-treated
SHRSP). Urinary protein and albumin excretion (19.0 1.5 and
5.8 1.0 mg/24 hr/bOg body wt, respectively) in TCV-116 (10
mg/kg/day)-treated SHRSP were not significantly different from
those in WKY, while there was a significant difference in urinary
protein and albumin excretion between WKY and enalapril (10
mg/kglday)-treated SHRSP (P < 0.05). Figure 1C and D indicate
that BUN (34.0 6.2 mg/dl) and plasma creatinine concentration
(0.648 0.085 mg/dl) in SHRSP were significantly higher than
those in WKY (16.6 0.5 and 0.304 0.009 mg/dl, respectively;
P < 0.01). TCV-116 at the three doses or enalapril significantly
lowered BUN and plasma creatinine concentrations in SHRSP
(P < 0.01).
Effects of TCV-116 and enalapnl on PRC and renal renin mRNA
As shown in Figure 2A, the mean value of plasma renin
concentration in vehicle-treated SHRSP (86 16 ng Ang I/hr/ml)
was 5.4-fold higher than that in WKY (P < 0.01). Ten weeks of
treatment with TCV-116 (0.1 or 1 mg/kg/day) or enalapril (10
mg/kg/day) did not change plasma renin levels in SHRSP. How-
ever, TCV-116 (10 mg/kg/day) increased PRC in SHRSP by
5.1-fold (P < 0.01). Renal renin mRNA levels, corrected for
GAPDH mRNA levels, in vehicle-treated SHRSP was 2.8-fold
higher compared with WKY (Figs. 2B and 3). TCV-116 (0.1
mg/kg/day) or enalapril (10 mg/kg/day) did not alter renal renin
mRNA levels in SHRSP, while TCV-116 at the dose of 1 and 10
mg/kg/day increased renal renin mRNA in SHRSP 1.6-fold (P <
0.05) and 3.6-fold (P < 0.01), respectively.
Effects of TCV-116 and enalapril on renal mRNA levels for TGF-
pi and extracellular matrix components in the interstitium and the
basement membrane
Figure 4 shows that renal TGF-f31 mRNA levels in SHRSP
were 3.4-fold higher than WKY (P < 0.01). Ten weeks of
treatment with TCV-116 at the three doses and with 10 mg/kg/day
of enalapril significantly decreased renal TGF-131 mRNA levels in
SHRSP, whose levels were all similar to those in WKY.
As shown in Figure 5, renal mRNA levels for types I and III
collagen and fibronectin in vehicle-treated SHRSP were 5.6-, 4.3-
and 2.8-fold, respectively, higher than WKY (P < 0.01). TCV-116
at all three doses used or enalapril significantly decreased mRNA
levels for these three extracellular matrix components in SHRSP
(P < 0.01). Furthermore, there was no significant difference
between TCV-1 16 (1 mg/kg/day) and enalapril (10 mg/kg/day)-
treated SHRSP, in renal mRNA levels for these three extracellu-
lar matrix components.
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Histological findings in the kidney
Figures 7 and 8 show photomicrographs of Azan-stained renal
sections from WKY and SHRSP treated with vehicle or TCV-116
for 10 weeks, and Table 2 summarizes the score index. In
vehicle-treated SHRSP (N 5), fibrinoid necrosis was observed
in the glomeruli. The renal tubules showed prominent lesions
including atrophy of the epithelium, hypertrophy of the basement
membrane, hyaline cast formation and dilatation. The arterioles
showed prominent hypertrophy and fibrinoid necrosis, and the
significant interstitial fibrosis was observed. Treatment with TCV-
_____
116 (0.1 mg/kg/day; N = 5) tended to improve all the above-
_____
mentioned lesions in SHRSP except for the hypertrophy of the
arterioles, as shown by the mean value of the score index,
although there was no statistically significant improvement. Enal-
april (10 mg/kg/day; N = 5) significantly improved fibrinoid
necrosis of the glomeruli and hyalinoid hypertrophy of arterial
intima, but there was no statistically significant improvement in
other parameters. On the other hand, TCV-116 (10 mg/kg/day;
N = 5) improved the above-mentioned renal lesions in SHRSP
more extensively than Enalapril (10 mg/kg/day), as judged by
score index. Neither fibrinoid necrosis of the glomeruli and
arterioles nor hypertrophy of the arteries and arterioles were seen
in the kidney of SHRSP treated with TCV-116 (10 mg/kg/day;
Table 2 and Fig. 7e, 1). Furthermore, compared with vehicle-
treated SHRSP, the score in TCV-116 (10 mg/kg/day)-treated
SHRSP was significantly smaller for hypertrophy of the basement
membrane, hyaline cast formation and dilatation, and atrophy of
the epithelium in the renal tubules (Fig. 8). Interstitial fibrosis
tended to be improved by TCV-116 (10 mg/kg/day), although
_____ there was no statistically significant difference. The score in the
kidney of WKY was 0 for all parameters.
______
Discussion
In the present study, we examined the in vivo gene expression of
TGF-pl, and extracellular matrix components in the kidney of
SHRSP rats in the malignant phase, and also examined the
long-term effects of an AT1 receptor antagonist and an ACE
inhibitor on the gene expression. We found that the gene expres-
sion of renal TGF-131, types I and III collagen, fibronectin and
type IV collagen are enhanced in the malignant phase of SHRSP
rats. Blockade of AT1 receptor by TCV-116 led to the significant
inhibition of these gene expressions as well as the improvement of
renal function. Furthermore, in spite of no decrease in blood
pressure, treatment with 0.1 mg/kg/day of TCV-116 in SHRSP rats
significantly reduced the above mentioned gene expressions, being
accompanied by the renal protective effects. Thus, the present
study demonstrates that intrarenal AT1 receptors play an impor-
tant role in renal injury of SHRSP rats and that the enhanced
gene expression of renal TGF-J31 in SHRSP rats is at least in part
mediated by renal AT1 receptor, independent of systemic blood
pressure.
SHRSP rats, a substrain of SHR, are considered a useful model
of human malignant hypertension and characteristically develop
extensive end-organ damage, including severe nephrosclerosis
[2—4]. However, the mechanism of renal sclerosis in hypertension
is not known. Furthermore, it is unclear which factors can
contribute to the progression of nephrosclerosis in hypertension.
TGF-131, a multifunctional growth factor, participates in tissue
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Fig. 2. Plasma renin concentration (A) and renal renin mRNA (B) in WKY
and SHRSP after 10 weeks of treatment with vehicle, TCV-116 or enalapril.
(A) Because the values of plasma renin concentrations showed heterosce-
dasticity, logarithmic transformation was made for data before statistical
analysis. (B) The ordinate shows renal renin mRNA values divided by
GAPDH mRNA values. The mean value of renin mRNA corrected for
GAPDH mRNA in WKY is represented as 1. PRC, plasma renin
concentration. W, V, T (0.1), T (1), T (10) and E (10) indicate the same
abbreviations as Figure 1. Each bar represents the mean Each group
included 5 animals. t P < 0.05, * P < 0.01 vs. V (vehicle-treated SHRSP).
NS, not significant vs. V (vehicle-treated SHRSP).
Figure 6 shows mRNA levels for extracellular matrix compo-
nents in the basement membrane. Type IV collagen mRNA levels
in vehicle-treated SHRSP were 2.1-fold higher than WKY (P <
0.01), and were significantly decreased by treatment with TCV-
116 or enalapril, to similar levels to WKY(Fig. 6A). On the other
hand, mRNA levels for laminin Bi (Fig. 6B) were not different
between WKY and SHRSP, and were unaffected by TCV-1 16 or
enalapril.
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Fig. 3. Autoradiograms of northern blot analysis
of mRNA for renin, TGF-131, type I collagenFibronectin (collagen I), type III collagen (collagen III),
fibronectin, type IV collagen (collagen IV),
laminin Bi and glyceraldehyde-3-phosphate
Collagen IV dehydrogenase (GAPDH) in WKY and SHRSP
after 10 weeks of treatment with vehicle, TCV-116
or enalapnl. Each blot was a single blot (The
northern blot analysis of all RNA samples was
Laminin Bi carried out on the same blot). The
autoradiograms of 2 typical samples of 5
different samples from each group were used as
the representative autoradiograms. W, V, T
GAPDH (0.1), T (1), T (10) and E (10) indicate the
same abbreviations as Figure 1.
repair and regeneration following tissue injury [18], and is re- 4
ported to participate in fibrotic diseases in various organs includ-
ing the kidney, by markedly stimulating synthesis of extracellular ]l. *p<o.o1
matrix proteins [19—24]. Border et al [21] have reported that
glomerular TGF-/31 expression and extracellular matrix accumu- 3 -
lation are increased in the mesangial proliferative glomerulone-
phritis, produced by a single injection of antithymocyte serum into
rats, and that the administration of anti-TGF-131 antibody into <
such glomerulonephritic rats significantly suppresses glomerular 2 -
*
extracellular matrix deposition. Elevated expression of TGF-131 JL * *
has also been reported in crescentic glomerulonephritis of rabbits, ( *
-r *
induced by injecting antibody against antigens of the glomerular 1 I
______
basement membrane [22], and in obstructive nephropathy of rats i I I I I 1 '
with unilateral ureteral ligation [23], which possibly promotes I I I I I I I
renal fibrosis. Furthermore, Isaka et al, who introduced TGF-/3 I I I I i I I
gene into the rat kidney via the renal artery using in vivo 0 — — I I I I I I
transfection technique, have found that the overexpression of W V T T T E
TGF-pl in the kidney induces glomerulosclerosis characterized by (0.1) (1) (10) (10)the accumulation of extracellular matrix proteins, thereby sup-
I Iporting that the increase in TGF-f31 is responsible for glomeru-
losclerosis in vivo [42]. Thus, TGF-/31 has been shown to contrib- SHRSP
ute to glomerulosclerosis and fibrosis in several renal diseases. Fig. 4. TGF-f31 mRNA levels in WKY and SHRSP after 10 weeks of
However, the gene expression and possible role of TGF-131 in treatment with vehicle, TCV-116 or enalapril. The ordinate shows TGF-131
hypertension-induced renal injury remain to be determined. mRNA levels corrected for GAPDH mRNA levels. The mean value of
In the present study, we found that the steady state mRNA TGF-131 mRNA corrected for GAPDH mRNA in WKY is represented as
1. W, V, T (0.1), T (1), T (10) and E (10) indicate the same abbreviations
levels for TGF-jJl are increased in the kidney of SHRSP. To as Figure 1. Each bar represents the mean SE. Each group included 5
examine whether the enhanced expression of renal TGF-/31 animals. ' P < 0.01 vs. V (vehicle-treated SHRSP).
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* -r
tmu
participates in renal fibrosis in SHRSP, we measured mRNA
levels for extracellular matrix components in the interstitium
(types I and III collagen and fibronectin), and the basement
membrane (type IV collagen). Northern blot analysis indicated
that the renal mRNA levels for the above-mentioned extracellular
matrix components were significantly elevated in SHRSP, com-
pared with WKY. Furthermore, our present histological observa-
tions by Azan staining of renal sections showed the increased
interstitial collagen fibers (composed of types I and III collagen)
and thickening of tubular basement membranes (mainly com-
posed of type IV collagen) in SHRSP (Table 2), thereby support-
ing that the increased expressions of collagen mRNAs led to the
Fig. 5. ,nRl'JA levels for extracellular matrix components in WKY and
SHRSP after 10 weeks of treatment with vehicle, TCV-116 or enalapril. The
ordinate in (A), (B) and (C) represents type I collagen, type III collagen
and fibronectin mRNA levels, respectively, corrected for GAPDH mRNA
levels. The mean value of each mRNA corrected for GAPDH mRNA in
WKY is represented as 1. W, V, T (0.1), T (1), T (10) and E (10) indicate
the same abbreviations as Figure 1. Each bar represents the mean SE.
Each group included 5 animals. P < 0.01 vs. V (vehicle-treated SHRSP).
increased collagen proteins. Thus, TGF-j31 may play an important
role in nephrosclerosis in SHRSP, by stimulating the gene expres-
sion of extracellular matrix components in the interstitium and the
basement membrane.
Accumulating evidence show that renin-angiotensin system is
responsible for the pathophysiology of various renal diseases
[6—15, 43]. Very recently, using the methods of in vitro autora-
diography [44], reverse transcription-polymerase chain reaction
(RT-PCR) [45] or in situ hybridization [46, 47], several groups of
investigators have reported that AT1 receptor is widely distrib-
uted in the glomeruli, blood vessels and tubules within the kidney,
although the pathophysiological role of renal AT1 receptor is not
A B
5
*P<0.01
= 4IL
*ii 10
*
I I
2
I
ci
a-
C
C)
0()
=
ci0
a
.
C0
LL
8
6
4
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4
3
2
1
0
W V T T T E
(0.1) (1) (10) (10)
0
W V T I T E
(0.1) (1) (10) (10)
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C
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*
*
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*
*P<0.01
*
W V T T T E
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A fully determined. Furthermore, in vitro study using cultured
vascular smooth muscle cells indicates that Ang II stimulates
TGF-f31 gene expression, which play an important role in cellular
*p<o.o hypertrophy or proliferation [48]. However, the possible contri-
bution of Ang II to TGF-/31 expression in vivo is still unclear.
In the present study, we investigated whether or not AT1
receptor in vivo is involved in renal TGF-31 gene expression in
SHRSP. Of note are the observations that in spite of no decrease
in blood pressure, 10 weeks of treatment with 0.1 mg/kg/day of
TCV-116 significantly inhibited the gene expression of renalJa _____ TGF-pl in SHRSP, accompanied by the significant decrease in
_______ extracellular matrix gene expressions. These inhibitory effects
were associated with the renal protective effects, as shown by the
significant decrease in renal weight, urinary protein and albumin
excretion, BUN, and plasma creatinine concentrations. Further-
more, in separate experiments, we examined the effect of TCV-
_______
-
________ _____
116 on the gene expression of TGF-31 and extracellular matrix
proteins in the kidney of deoxycorticosterone acetate (DOCA)-
salt hypertensive rats, and found that three weeks of treatment
with TCV-116, without lowering blood pressure throughout the
treatment, significantly reduced renal TGF-31 mRNA levels of
DOCA-salt hypertensive rats, being accompanied by the suppres-
sion of extracellular matrix gene expressions [49]. Thus, the
present study, taken together with our data on DOCA-salt
hypertensive rats [491, support the notion that the inhibition of
renal TGF-f31 gene expression by TCV-116 is not mediated by
B systemic blood pressure but by the direct inhibition of renal AT1
receptor. AT1 receptor may be responsible for the accumulation
of extracellular matrix in the kidney of SHRSP, by stimulating
TGF-f31 gene expression. However, the suppression of renal types
I and III collagen mRNA levels by TCV-116 in SHRSP was not
complete but partial, thereby indicating that not only TGF-/31 but
also other unknown factors play an important role in the enhance-
NS ment of these collagen gene expressions in SHRSP.
In the present study, TCV-116 tended to improve renal inter-
stitial fibrosis in SHRSP, as estimated by the score index of renal
histology, although there was no statistically significant improve-
ment. However, TCV-116 at all three doses significantly de-
creased not only urinary protein excretion but also renal weight,
BUN and plasma creatinine levels in SHRSP, thereby confirming
that TCV-1 16 significantly prevented the development of renal
injury in SHRSP. Furthermore, in DOCA-salt hypertensive rats,
the decrease in renal collagen mRNA levels by TCV-116 was
associated with the significant improvement of renal interstitial
fibrosis [score index of interstitial fibrosis: 1.1 0.2 (Vehicle
group, N = 14) vs. 0.6 0.2 (TCV-116 treatment, N 14), P C
I I 0.05] [49]. In addition, our present histological analysis by the
score index allows for semi-quantitative analysis, but does not for
quantitative analysis. These findings, taken together with our
results on the partial normalization of types I and III collagen
mRNAs by TCV-116, suggest that the technical limitation of our
histological analysis might not allow us to detect the partial
normalization of interstitial collagen accumulation by TCV-116 in
SHRSP. However, the present study cannot exclude the possibility
that the decrease in collagen mRNA levels might not lead to the
decrease in interstitial collagen accumulation, because the accu-
mulation of interstitial collagen in the tissue may be affected not
only by the transcriptional rate of collagen gene but also by the
*
*
-
* *
W V T T I E
(0.1) (1) (10) (10)
SHRSP
3
I0 2
U-
'Ca
C
a)0)
a)
0
3
Io20
'C
C
C
E31
0
SHRSP
Fig. 6. mRNA levels for renal extracellular matrix components in the
basement membrane in WKY and SHRSP after 10 weeks of treatment The
ordinate in (A) and (B) represents type IV collagen and laminin Bi chain
mRNA levels, respectively, corrected for GAPDH mRNA levels. The
mean value of each mRNA corrected for GAPDH mRNA in WKY is
represented as 1. W, V, 1 (0.1), T (1), T (10) and E (10) indicate the same
abbreviations as Figure 1. Each bar represents the mean Each group
included 5 animals. * P < 0.01 vs. V (vehicle-treated SHRSP). NS, not
significant vs. V (vehicle-treated SHRSP).
MS
MS NS
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Fig. 7. Light microscopy of renal cortex from WKY (a and b), vehicle-treated SHRSP (c and d) and TCV-116(1O mg/kg/day) -treated SHRSP (e and f). The
arrows in (b), (d) and (I) show arteriole. In SHRSP treated with vehicle, interstitial fibrosis were observed (c), and prominent hypertrophy of the
arteriole was observed (the arrow in d). On the other hand, in TCV-116 (10 mg/kg/day)-treated SHRSP, the renal tubules (e) and the arteriole (the
arrow in I) were normal. No interstitial fibrosis was found in 2 of 5 SHRSP treated with TCV-116 (10 mg/kg/day). Azan stain; X 225 (a, c, e), X 300
(b, d, t).
translational rate, posttranslational modification and the degra- Previous reports support that ACE inhibitor or AT1 receptor
dation rate. Further study is needed to elucidate the regulatory antagonist reduces intrarenal, especially intraglomerular, blood
mechanism of collagen accumulation. pressure via blocking the local renin-angiotensin system, and the
'a.
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Fig. 8. High magnifications of light microscopy
of renal sections from WKY(a), vehicle-treated
SHRSP (b) and TCV-116 (10 mg/kg/day) -treated
SHRSP (c). (b) Atrophy of the epithelium and
hypertrophy of the tubular basement
membranes were prominent in vehicle-treated
SHRSP. (c) TCV-116 (10 mg/kg/day) treatment
significantly improved the above-mentioned
renal lesions. Azan stain; X 530.
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Table 2. Score index of the kidney from SHRSP after 10 weeks of
treatment with vehicle, TCV-116 (0.1 mg/kg/day), TCV-116 (10 mg/kg!
day) or enalapril (10 mg/kg/day)
Vehicle
TCV
(0.1 mg)
TCV
(10 mg)
Enalapril
(10 mg)
Glomerulus
Fibrinoid necrosis 1.4 0.4 1.2 0.6 0 a 0.2 0.2
Renal tubules
Atrophy 2.2 0.2 1.8 0.4 0.4 O.2' 1.8 0.6
Hypertrophy of 1.8 0.2 1.2 0.4 0.2 02b 1.2 0.5
basement membrane
Hyaline cast with 2.6 0.2 2.2 0.5 0.8 0.2" 1.8 0.6
dilatation
Arteriole
Fibrinoid necrosis 1.6 0.2 1.2 0.6 0 0" 0.6 0.4
Hypertrophy 1.2 0.5 1.4 0.6 0 0 0.8 0.4
Artery
Hyalinoid hypertrophy 1.2 0.4 0.2 0.2 0 0 0 0
of intima
Interstitial fibrosis 1.4 0.4 1.2 0.4 0.8 0.4 1.2 0.5
The values represent the mean Each group included 5 animals.
Abbreviations are: SHRSP, stroke-prone spontaneously hypertensive rats;
Vehicle, treatment with vehicle; TCV (0.1 mg), treatment with TCV-116
(0.1 mg/kg/day); TCV (10 mg), treatment with TCV-116 (10 mg/kg/day);
Enalapril (10 mg), treatment with enalapril (10 mg/kg/day).
ap.< 0.05, bP < 0.01 vs. vehicle-treated SHRSP
renal beneficial effects of these drugs may be at least in part due
to the improvement of intrarenal hemodynamics [8, 9, 11, 12].
Riser et a!, who examined the effects of glomerular capillary
distension and mesangial cell stretching on extracellular matrix
synthesis, have suggested that capillary expansion and stretching
of mesangial cells by glomerular hypertension provoke increased
extracellular matrix production [50]. Therefore, it cannot be ruled
out that the suppression of TGF-/31 or extracellular matrix
expressions by TCV-116 might be mediated by the intrarenal
hemodynamic improvement.
In viva inhibition of Ang II production by ACE inhibitors
increases the biosynthesis and secretion of renal renin [31, 51],
because Ang II has a negative feedback effect on renal renin
expression. In the present study, 10 mg/kg/day of TCV-116
dramatically elevated renal renin mRNA and plasma renin levels,
thereby indicating the major role of AT1 receptor on juxtaglo-
merular cells [47] in negative feedback regulation of renin expres-
sion. Very interestingly, despite the marked reduction of renal
TGF-/31 and extracellular matrix components, treatment with 0.1
mg/kg/day of TCV-116 did not alter renal renin mRNA and
plasma renin levels. These observations reveal that this AT1
receptor antagonist can inhibit renal gene expression of TGF-/31
and extracellular matrix components at lower concentrations than
those that stimulate renin gene expression in SHRSP.
Previously we reported that circulating prorenin (the biosyn-
thetic precursor of renin) is activated within the kidney but not in
the blood circulation [52], and suggested that intrarenal activation
of prorenin may be enhanced in SHRSP [53]. Moreover, we have
obtained the evidence that renal angiotensin II levels, measured
by HPLC separation coupled with specific radioimmunoassay, are
increased at the malignant phase of SHRSP [541. These findings
support that intrarenal renin-angiotensin system may be activated
in SHRSP. In the present study, as shown in Figure 2, renal renin
mRNA and plasma renin were increased in SHRSP compared
with WKY, indicating the increased synthesis of renal renin in
SHRSP. All these findings allow us to assume that the enhance-
ment of renal TGF-$31 gene expression in SHRSP may be due to
the activation of intrarenal renin-angiotensin system. Thus, the
potent suppressive effect of TCV-116 on TGF-pl gene expression
in SHRSP appears to be in part explained by the inhibition of
intrarenal renin-angiotensin system. However, the possible con-
tribution of circulating renin-angiotensin system to TGF-pl gene
expression cannot be excluded, because plasma active renin levels
were increased in SHRSP.
The renal source of increased TGF-131 mRNA in SHRSP was
not investigated in this study. Previous report on immunohisto-
chemical localization of TGF-pl shows that immunoreactive
TGF-J31 protein is mainly localized in tubular epithelial cells of
normal rat kidney [55]. However, in the kidney of rats with
experimental glomerulonephritis, immunoreactive TGF-131 pro-
tein is significantly expressed in glomerular cells as well as
epithelial cells [56]. Very recently, using northern blot analysis
and in situ hybridization technique, Yamamoto et al have exam-
ined the gene expression of renal TGF-131 in rats with progressive
kidney fibrosis which was produced by two injections of anti-
mesangial serum [57]. These investigators have found that
TGF-/31 mRNA is increased in glomerular cells and interstitial
cells in the kidney of such rats, which leads to the increased
TGF-131 protein in glomerular cells and interstitial cells, followed
by the development of glomerulosclerosis and tubulointerstitial
fibrosis. Therefore, they have proposed that the elevated gene
expression of TGF-f31 contributes to the development of glomer-
uloscierosis and tubulointerstitial fibrosis [57]. However, histolog-
ical study, using in Situ hybridization and immunohistochemical
techniques, is needed to elucidate the exact source of the in-
creased TGF-3l expression in SHRSP.
TGF-131 is secreted mainly in an inactive latent form, which has
no biological function including extracellular matrix production
[58, 59], thereby suggesting that the activation of the latent form
of TGF-31 may be a crucial regulatory step to determine active
TGF-j31 levels. It has been suggested that platelets may play a role
in renal glomerular lesions by activating latent TGF-pl [60]. On
the other hand, the investigation on anti-basement membrane
glomerulonephritis in the rabbit suggests that some renal cells
may secrete directly active TGF-/31 [221. Thus, the mechanism of
activation of latent TGF-pl in viva remains to be elucidated. The
present study did not allow us to determine whether or not the
increased TGF-j31 mRNA levels lead to the secretion of the active
form of TGF-131.
In conclusion, we obtained evidence that the gene expression of
renal TGF-f31 is increased at the malignant phase of SHRSP,
which may contribute to the increased gene expression of renal
extracellular matrix components in the interstitium and the base-
ment membrane. AT1 receptor seems to be involved in the
increased TGF-/31 expression in SHRSP. Thus, we propose that
independent of hypertension, renal AT1 receptor may play an
important role in nephrosclerosis in SHRSP.
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